A Phase 2 interventional study of Islatravir and Ulonivirine in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency virus type 1 (HIV-1) who have been virologically suppressed for ≥6 months on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily.
Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program and as described in protocol amendment 2 (approved 01-Dec-2021), participants in study Part 1 (double-blind treatment period) were unblinded, discontinued all study interventions, and switched to standard of care non-study antiretroviral (ART) therapy. Participants who received ISL + ulonivirine (Groups 1 to 3) may have then entered into an unblinded safety monitoring period and were monitored for ≥6 months. As specified in protocol amendment 2, study Parts 2 and 3 were no longer planned or initiated for any participant.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive ISL 20 mg + ulonivirine 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD). Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.
Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to Ulonivirine · Drug: Placebo to BIC/FTC/TAF
Participants receive ISL 20 mg + ulonivirine 200 mg QW and placebo to BIC/FTC/TAF QD. Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.
Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to Ulonivirine · Drug: Placebo to BIC/FTC/TAF
Participants receive ISL 20 mg + ulonivirine 400 mg QW and placebo to BIC/FTC/TAF QD. Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.
Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to BIC/FTC/TAF
Participants receive placebo to ISL + placebo to ulonivirine QW and BIC/FTC/TAF 50 mg/200 mg/25 mg QD.
Drug: BIC/FTC/TAF · Drug: Placebo to ISL · Drug: Placebo to Ulonivirine
ISL capsule taken by mouth.
Also known as: MK-8591
Ulonivirine tablet taken by mouth.
Also known as: MK-8507
Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide
BIC/FTC/TAF tablet taken by mouth.
Also known as: BIKTARVY®
Placebo capsule matched to ISL taken by mouth.
Placebo tablet matched to ulonivirine taken by mouth.
Placebo tablet matched to BIC/FTC/TAF taken by mouth.
Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and supplemental statistical analysis plan (sSAP), presented here is the percentage of participants who experienced one or more AEs during the Double-blind Treatment Period and includes the 42 days following the final dose of double-blind study intervention.
Time frame: Up to approximately 9 months
Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who discontinued double-blind study intervention due to an AE during the Double-Blind Treatment Period.
Time frame: Up to approximately 8 months
Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who experienced one or more AEs during the Unblinded Safety Monitoring Period, beginning 42 days following the final dose of double-blind study intervention.
Time frame: Up to approximately 37 months
| Milestone | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF |
|---|---|---|---|---|
| Started | 40 | 41 | 40 | 40 |
| Completed | 37 | 39 | 38 | 39 |
| Not completed | 3 | 2 | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Physician decision | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 1 | 0 | 0 |
| Milestone | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF |
|---|---|---|---|---|
| Started | 37 | 39 | 37 | 0 |
| Completed | 25 | 25 | 24 | 0 |
| Not completed | 12 | 14 | 13 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 | 1 | 0 |
| Withdrew: Sponsor decision | 5 | 6 | 4 | 0 |
| Withdrew: Withdrawal by subject | 6 | 7 | 7 | 0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and supplemental statistical analysis plan (sSAP), presented here is the percentage of participants who experienced one or more AEs during the Double-blind Treatment Period and includes the 42 days following the final dose of double-blind study intervention.
| Percentage of Participants | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF |
|---|---|---|---|---|
| Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind | 75.0 | 75.6 | 80.0 | 67.5 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who discontinued double-blind study intervention due to an AE during the Double-Blind Treatment Period.
| Percentage of Participants | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF |
|---|---|---|---|---|
| Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period | 0.0 | 4.9 | 2.5 | 0.0 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who experienced one or more AEs during the Unblinded Safety Monitoring Period, beginning 42 days following the final dose of double-blind study intervention.
| Percentage of Participants | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg |
|---|---|---|---|
| Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period | 56.8 | 56.4 | 67.6 |
Collected over Up to approximately 46 months (Double-blind Treatment Period: AEs were assessed at the participant level for up to approximately 9 months [from randomization to 42 days after last double-blind study intervention]; Unblinded Safety Monitoring Period: AEs were assessed at the participant level for up to approximately 37 months [beginning 42 days after the final double-blind study intervention to last participant data collection]). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ISL 20 mg + MK-8507 100 mg QW | 0/40 (0%) | 2/40 (5%) | 18/40 (45%) |
| ISL 20 mg + MK-8507 200 mg QW | 0/41 (0%) | 3/41 (7.3%) | 15/41 (36.6%) |
| ISL 20 mg + MK-8507 400 mg QW | 0/40 (0%) | 1/40 (2.5%) | 25/40 (62.5%) |
| BIC/FTC/TAF QD | 0/40 (0%) | 0/40 (0%) | 14/40 (35%) |
| ISL 20 mg + MK-8507 100 mg QW → Non-study ART | 0/37 (0%) | 0/37 (0%) | 8/37 (21.6%) |
| ISL 20 mg + MK-8507 200 mg QW → Non-study ART | 0/39 (0%) | 0/39 (0%) | 16/39 (41%) |
| ISL 20 mg + MK-8507 400 mg QW → Non-study ART | 0/37 (0%) | 1/37 (2.7%) | 16/37 (43.2%) |
| Event | ISL 20 mg + MK-8507 100 mg QW | ISL 20 mg + MK-8507 200 mg QW | ISL 20 mg + MK-8507 400 mg QW | BIC/FTC/TAF QD | ISL 20 mg + MK-8507 100 mg QW → Non-study ART | ISL 20 mg + MK-8507 200 mg QW → Non-study ART | ISL 20 mg + MK-8507 400 mg QW → Non-study ART |
|---|---|---|---|---|---|---|---|
| Skin lacerationInjury, poisoning and procedural complications | 0/40 | 0/41 | 0/40 | 0/40 | 0/37 | 0/39 | 1/37 |
| Device related thrombosisGeneral disorders | 1/40 | 0/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Campylobacter gastroenteritisInfections and infestations | 1/40 | 0/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| CellulitisInfections and infestations | 1/40 | 0/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Kaposi's sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/40 | 0/41 | 1/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Acute myocardial infarctionCardiac disorders | 0/40 | 1/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Non-cardiac chest painGeneral disorders | 0/40 | 1/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Renal colicRenal and urinary disorders | 0/40 | 1/41 | 0/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| Event | ISL 20 mg + MK-8507 100 mg QW | ISL 20 mg + MK-8507 200 mg QW | ISL 20 mg + MK-8507 400 mg QW | BIC/FTC/TAF QD | ISL 20 mg + MK-8507 100 mg QW → Non-study ART | ISL 20 mg + MK-8507 200 mg QW → Non-study ART | ISL 20 mg + MK-8507 400 mg QW → Non-study ART |
|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 3/40 | 4/41 | 7/40 | 3/40 | 4/37 | 7/39 | 11/37 |
| DiarrhoeaGastrointestinal disorders | 1/40 | 3/41 | 6/40 | 0/40 | 2/37 | 2/39 | 0/37 |
| FatigueGeneral disorders | 4/40 | 3/41 | 5/40 | 2/40 | 1/37 | 0/39 | 2/37 |
| Accidental overdoseInjury, poisoning and procedural complications | 2/40 | 2/41 | 4/40 | 5/40 | 0/37 | 0/39 | 0/37 |
| HeadacheNervous system disorders | 5/40 | 1/41 | 4/40 | 0/40 | 0/37 | 0/39 | 0/37 |
| NauseaGastrointestinal disorders | 2/40 | 2/41 | 4/40 | 1/40 | 0/37 | 0/39 | 0/37 |
| Back painMusculoskeletal and connective tissue disorders | 1/40 | 1/41 | 4/40 | 2/40 | 1/37 | 2/39 | 1/37 |
| ConstipationGastrointestinal disorders | 1/40 | 0/41 | 3/40 | 2/40 | 0/37 | 0/39 | 1/37 |
| NasopharyngitisInfections and infestations | 2/40 | 0/41 | 2/40 | 3/40 | 1/37 | 1/39 | 1/37 |
| SinusitisInfections and infestations | 3/40 | 0/41 | 1/40 | 0/40 | 2/37 | 0/39 | 0/37 |
| Age, Continuous(Years) | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF | Total |
|---|---|---|---|---|---|
| Mean | 43.7 ± 12.1 | 46.5 ± 10.8 | 43.5 ± 12.6 | 47.9 ± 11.6 | 45.4 ± 11.8 |
| Sex: Female, Male(Participants) | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF | Total |
|---|---|---|---|---|---|
| Female | 9 | 8 | 6 | 8 | 31 |
| Male | 31 | 33 | 34 | 32 | 130 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 6 | 8 | 28 |
| Not Hispanic or Latino | 30 | 30 | 32 | 32 | 124 |
| Unknown or Not Reported | 4 | 3 | 2 | 0 | 9 |
| Race (NIH/OMB)(Participants) | Group 1: ISL 20 mg + Ulonivirine 100 mg | Group 2: ISL 20 mg + Ulonivirine 200 mg | Group 3: ISL 20 mg + Ulonivirine 400 mg | Group 4: BIC/FTC/TAF | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 0 | 0 | 2 |
| Asian | 0 | 2 | 0 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 14 | 13 | 13 | 50 |
| White | 27 | 24 | 27 | 26 | 104 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Mar 2021 to primary completion in Jan 2025, 46 months.
Results were first posted in Jan 2026, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Islatravir · Ulonivirine